PBM Trade Group " A Summary of Insulin Coverage in Medicare Part D " Study from Milliman, Inc. Health

The PBM trade group known as the Pharmaceutical Care Management Association (PCMA) recently commissioned Milliman Health to conduct a study of Medicare beneficiaries enrolled in a Part D Plan to determine if they " prefer " brand-name basal insulins over the biosimilar Semglee which is made by Biocon (currently commercialized by Viatris, although Biocon recently announced it was acquiring Viatris half of their joint venture). In reality, it is little more than smoke and mirrors from a PBM trade group.The reason PCMA commissioned the study was to try and generate " evidence " that patients somehow prefer costly, heavily-rebated branded insulins over biosimilars. The study can be seen athttps://www.pcmanet.org/wp-content/uploads/2022/06/6-7-22-Insulin-Landscape-Summary-report.pdfIf you visit slide #7 (the one which addresses " Long-Acting Insulin " ), that addresses the reality that many Medicare Part D plan members are covered by a plan which now " prefers " Biocon ' s Semglee over Sanofi ' s Lantus. Cigna ' s Express Scripts last year dropped Sanofi Lantus in favor of Semglee (likewise, the PBM known as Prime Therapeutics also preferred Semglee, although Prime relies upon Express Scripts for price negotiations and retail pharmacy coverage). So far, there are a handful of basal glargine biosimilars including Semglee, another unbranded version called Viatris U-100 Insulin Glargine, as well as two made by Lilly including Basaglar and another which will be branded as Rezvogl...
Source: Scott's Web Log - Category: Endocrinology Tags: 2022 Biosimilar biosimilars insulin PBM PCMA Source Type: blogs